BlueControl: A New Way to Treat Psoriasis Vulgaris


Philips, the pioneers of lighting technology, recently announced that it will be releasing a new device which will help treat mild to moderate cases of psoriasis vulgaris without having to opt for any kind of medication. The device is called BlueControl and it uses a group of LEDs which shine the blue light onto the skin so that the high rate at which cells divide is kept under control.

Psoriasis vulgaris is a chronic skin disease which can actually impact every aspect of a patient’s life. Traditional therapies are found to be problematic, time consuming and can lead to numerous other side effects. So, a research was conducted and it was shown that when the skin is irradiated with blue light, it stimulates certain natural processes and effects.

So, the brains behind BlueControl harnessed these effects to develop a wearable medical device which to some extent reduces the scaling, redness, thickness and extent of psoriasis vulgaris plaques. This therapy is quite effective and is very simple for a patient to combine it with his daily routine.

The patient can use BlueControl at any time and on any part for the body where the device can be strapped to. The device has only one single button to turn it off and on and it is battery powered. Once it is turned on, the 40 LEDs in it project high intensity light which doesn’t have a UV component in it for safety.

In order to launch BlueControl, Philips had to investigate the safety and effectiveness of it to reduce the symptoms of psoriasis vulgaris. Hence, two trials were conducted by Philips in partnership with University Hospitable of Aachen. Then, in the second trial which took place about four months ago; patients were treated for twelve weeks. Local Psoriasis Area Severity Index reported that the results showed a 50% reduction on the symptoms of the disease. Also, there were no side effects observed with the blue LED light treatment.

BlueControl will be introduced to international healthcare professionals at the EADV shortly and it will be prescribed by physicians and will be made available through the distributors across Germany, UK and the Netherlands from October 2014.


Via : News centre